ReviewDiscover nano2026
Cross database bibliometric and knowledge mapping analysis of nanoplatform mediated tumor associated macrophage reprogramming.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNanoplatforms are evolving from passive delivery vehicles into multifunctional engineered systems capable of remodeling the tumor microenvironment. Tumor-associated macrophages (TAMs) are important biological interfaces because of their abundance, plasticity, and roles in immune suppression and therapeutic resistance. However, the knowledge structure and developmental trajectory of nanoplatform-mediated TAM reprogramming remain insufficiently characterized.
methodsWe performed a bibliometric and knowledge-mapping analysis using independently retrieved Web of Science Core Collection (WoSCC) and Scopus datasets with cross-database comparison and consistency assessment. English-language articles and reviews published from January 1, 2007, to March 25, 2026, were included, yielding 1,474 WoSCC and 2,077 Scopus records. Analyses used bibliometrix, VOSviewer, CiteSpace, BiblioVista, and Scimago Graphica.
resultsPublication output increased markedly in both databases, particularly after 2019, with highly concordant annual trends (Spearman's ρ = 0.996, p < 0.001). The field was primarily represented in nanoscience, materials science, pharmacology, biomaterials, and biomedical engineering. China and the Chinese Academy of Sciences were the leading country and institution, while ACS Nano and Journal of Controlled Release formed the principal journal core. Keyword, burst, thematic, and milestone analyses supported a heuristic five-stage transition from macrophage-addressable nanodelivery to material-intrinsic immunomodulation, microenvironment-responsive TAM reprogramming, biomimetic and combinatorial nano-immunotherapy, and programmable innate-immunity-centered nanoplatforms. Translation-related themes remained comparatively less visible.
conclusionNanoplatform-mediated TAM reprogramming has developed into a rapidly expanding interdisciplinary research area linking nanoplatform engineering, macrophage-directed regulation, and tumor microenvironment remodeling. Future advancement will likely depend on increasingly sophisticated platforms alongside improved reproducibility, standardization, predictable in vivo behavior, and clinical translatability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.